Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 nipocalimab study in pregnancies at risk for severe HDFN
2022-502629-16-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in Erythroblastosis fetalis (HDFN) comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Composite pregnancy and neonatal success endpoint. Planned start Jul 2024; status: authorised.
02
Drugs
nipocalimab
03
Conditions
Erythroblastosis fetalis (HDFN)
Beyond the preview
Go deeper on 2022-502629-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502629-16-00.